Navigation Links
Single virus used to convert adult cells to embryonic stem cell-like cells
Date:12/15/2008

CAMBRIDGE, Mass. (Dec. 15, 2008) Whitehead Institute researchers have greatly simplified the creation of so-called induced pluripotent stem (iPS) cells, cutting the number of viruses used in the reprogramming process from four to one. Scientists hope that these embryonic stem-cell-like cells could eventually be used to treat such ailments as Parkinson's disease and diabetes.

The earliest reprogramming efforts relied on four separate viruses to transfer genes into the cells' DNA--one virus for each reprogramming gene (Oct4, Sox2, c-Myc and Klf4). Once activated, these genes convert the cells from their adult, differentiated status to an embryonic-like state.

However, this method poses significant risks for potential use in humans. The viruses used in reprogramming are associated with cancer because they may insert DNA anywhere in a cell's genome, thereby potentially triggering the expression of cancer-causing genes, or oncogenes. For iPS cells to be employed to treat human diseases, researchers must find safe alternatives to reprogramming with such viruses. This latest technique represents a significant advance in the quest to eliminate the potentially harmful viruses.

Bryce Carey, an MIT graduate student working in the lab of Whitehead Member Rudolf Jaenisch, spearheaded the effort by joining in tandem the four reprogramming genes through the use of bits of DNA that code for polymers known as 2A peptides. Working with others in the lab, he then manufactured a so-called polycistronic virus capable of expressing all four reprogramming genes once it is inserted into the genomes of mature mouse and human cells.

When the cells' protein-creating machinery reads the tandem genes' DNA, it begins making a protein. However, when it tries to read the 2A peptide DNA that resides between the genes, the machinery momentarily stops, allowing the first gene's protein to be released. The machinery then moves on to the second gene, creates th
'/>"/>

Contact: Nicole Giese
giese@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
2. Single-largest biodiversity survey says primary rainforest is irreplaceable
3. New technique captures chemical reactions in a single living cell at unprecedented resolution
4. Gene study supports single main migration across Bering Strait
5. Baumann lab identifies elusive telomere RNA subunit in single cell model
6. Ebola virus disarmed by excising a single gene
7. Blue-eyed humans have a single, common ancestor
8. Rice scientists make breakthrough in single-molecule sensing
9. Single-celled bacterium works 24-7
10. RevGenUK, a single-stop shop for use in functional genomics
11. Researchers observe spontaneous ratcheting of single ribosome molecules

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...s have had their hands tied because more than half...a protein called p53. As a critical anti-cancer wa...erations within cells. When cells lose p53, tumors..., These tumors might be tough, but they,re not in...rbor Laboratory (CSHL). The chink in the tumors, a...
(Date:11/9/2009)...has inspired a 3.2m, three-year research project t...f security, energy and the environment. The Univer...y QinetiQ have just signed a collaborative contrac...ing physical sciences research. , Over the next...ity of Exeter and QinetiQ will work together to de...
(Date:11/9/2009)...utritionist whose research was instrumental in add...fants and Children (WIC) food subsidy will receive...nding achievement in the field of maternal-fetal n...fessor in the Department of Community Health Scien...chool of Public Health, will receive the award to...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 1Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 2Rep Lewis Commends Kidney Care Partners Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Georgia 48216 3VA Awards 243 7 Million for New Hampshire Veterans Home 48212 1HMS Holdings Corp to Present at William Blair 29th Annual Growth Stock Conference 48209 1
... the University of Wisconsin-Madison is using musi... species in the state. , "Research shows music ...g memory, emotion, attitudes, and even behavior," ...es communication at UW-Madison and environmental c...w, who directed the project, recruited a group of ...
...008 SRI International announced today that it has ...s grant from the Bill & Melinda Gates Foundation. ...h research project conducted by Krishna Kodukula, ...enter for Advanced Drug Research (CADRE) in Shenan...ociate director of Proteomics and Protein Biochemi...
...he University of Houston to use technologies with ...tools that will help doctors and technicians bette...d neck cancer. , Dr. Ali Kamrani, founding direct...ory at UH and a former auto industry researcher, i...r and deputy research director of radiation physic...
Other Biology News:SRI International receives $100,000 Grand Challenges Explorations grant 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4
(Date:11/6/2009)...TEO, Calif., Nov. 6 ,... transfer of Qutenza(TM) E.U. Marketing Authorizat...ant progress in commercial readiness activities E...r Director, Marketing; and Director, Commercial Op...s director and Audit Committee chairman , U...
(Date:11/6/2009)... The agenda for Arrowhead’s 201...hich is set to take place on February 22-24, 2010 ... day conference we will highlight key issues in fo... share their experiences. , ... agenda for Arrowhead’s 2010 Personalized M...
(Date:11/5/2009)...PANY, N.J., Nov. 5 DSM Pharmaceuti...nufacturing alliance with Galenix, Saint Jean D,Il...rcial scale manufacturing partner for Galenix comm...alenix will collaborate on business development op...hnologies, based on the strength of Galenix in dru...
(Date:11/5/2009)... Neb., Nov. 5 Transgenom...d financial results for the quarter ended Septembe...esented in the tables that follow. ,, Third Qu...of $366,000 or $0.01 per share for the third quart...r $0.01 per share for the third quarter of 2008. ...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...fe Sciences,announced today that Richard Evans has...sibility will be providing advisory services to co... as well as selected investment,assignments in cap...ted,drug analyst, he will also have responsibility... in the capital markets area. "Richard brings us ...
... Presentations Accepted to Meeting, CAMBRIDGE, Ma...oday announced that 23 presentations will showcase...ts antibiotic drug discovery,platform at the upcom...robial Agents and Chemotherapy (ICAAC), taking pla... Ph.D., Chief Scientific Officer of Targanta Thera...
...al Partners and Versant Ventures Lead ...DISON, Wis., Sept. 12 OpGen, Inc., today announce...ity financing. The round,was led by CHL Medical Pa...ures, with previous investor Mason Wells also part...ecome chairman of the Board of,Directors and will ...
Other Biology Technology:Senior Research Analyst Richard Evans Joins AVOS Life Sciences 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 2Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 3Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 4Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 5Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 6Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting 7OpGen Announces $23.6 Million Series A Financing 2OpGen Announces $23.6 Million Series A Financing 3
Customized Competent E. coli. from Molecular Cloning Laboratories (MCLAB)
Fluorescent Standards Red Standard from Invitrogen
X-Gal from GE Healthcare, formerly Amersham Biosciences
Mouse Anti-Oligodendrocyte Marker O1 Monoclonal Antibody, Unconjugated, Clone O1 from R&D Systems
Biology Products: